Surbhi Sarna on Envision Medical, Ovarian Cancer Diagnostics, and Building Through Rejection

概览

This episode features Surbhi Sarna, a Y Combinator partner and former founder/CEO of Envision Medical. The conversation traces how a painful ovarian cyst experience at age 13 exposed her to the diagnostic gaps in women’s health and eventually pushed her toward building a medical device company.

Sarna explains how she developed a device concept to access the fallopian tube without surgery, why ovarian cancer may often originate there, and how user conversations with physicians shaped the product’s usability, safety, and clinical direction.

A major thread is the difficulty of fundraising as a young solo female founder in a category that investors did not yet recognize as “femtech.” The episode also covers FDA clearance, clinical studies, acquisition interest, the eventual sale to Boston Scientific, and the emotional complexity of letting go of a mission-driven company.

分段落总结

[00:25] Guest Introduction

[事实] Jessica Livingston and Carolyn Levy introduce Surbhi Sarna as a YC partner and the former founder and CEO of Envision Medical. [事实] Envision Medical built a device related to testing for ovarian cancer, and Sarna also published a book called Without a Doubt. [事实] The hosts frame the episode around Sarna’s personal health experience, company journey, and book.

[01:13] A Medical Scare at Age 13

[事实] Sarna first experienced severe pain while writing a school paper and passed out before her mother took her to the hospital. [事实] Doctors initially suspected appendicitis and nearly prepared her for surgery before reconsidering. [事实] A later transvaginal ultrasound showed large complex cysts on one ovary. [推测] The experience made the uncertainty and limitations of women’s health diagnostics personally vivid to her.

[05:41] Why Diagnosis Was So Difficult

[事实] Sarna explains that a fluid-filled cyst is usually less concerning, but her mass was “complex,” meaning partly solid and partly liquid. [事实] The blood test available for ovarian cancer was described as extremely inaccurate, especially for premenopausal women. [事实] She says many ovarian-removal surgeries happen each year in the U.S. despite far fewer ovarian cancer cases, and many cancers are still caught late. [事实] She explains that biopsy can be risky because taking a sample from a potentially cancerous ovarian mass could spread cells in the abdominal cavity. [推测] The core problem was not simply treatment, but the lack of a safe, accurate, early diagnostic pathway.

[08:36] Coping Through Research and Writing

[事实] Sarna says this happened around 2004, when she researched using Yahoo and the library rather than relying on Google. [事实] Teachers helped her understand scientific concepts, while an English teacher, Miss Middlestep, encouraged her to channel emotions into writing. [事实] Her mother’s support also helped her through the experience. [推测] Writing became both a coping mechanism and a foundation for the later memoir.

[10:34] The Cyst Resolves and a Long-Term Interest Begins

[事实] After about six months, the cyst burst while Sarna was in Spanish class, causing severe pain and an embarrassing school incident. [事实] She continued having cysts about once a year afterward, but each recurrence became less frightening because her family knew how to monitor it. [事实] She says the experience helped her see historical differences in how women’s health was prioritized. [推测] This repeated exposure helped turn a personal medical issue into a long-term entrepreneurial motivation.

[12:49] Why Startups, Not Just Research

[事实] Sarna’s father was a software engineer and one of the early employees at Netscape. [事实] She grew up around the excitement of Bay Area technology and startup culture. [事实] She describes herself as curious and experimental from childhood, including observing insects and trying to assemble a treadmill. [推测] Her path toward entrepreneurship came from combining scientific curiosity with an early model of startups as a way to build new things.

[15:21] Family Background and Education

[事实] Sarna’s mother has a PhD in Hindi literature and later taught Hindi at Stanford. [事实] Sarna went to Berkeley for undergrad and later worked in medtech, including at Abbott Vascular and another startup. [推测] Her family background combined technical, academic, and cultural influences rather than a single conventional startup path.

[16:44] The Decision to Start Envision Medical

[事实] Sarna was 24 when her grandmother’s breast cancer returned and later passed away. [事实] She had spent a summer in India helping care for her grandmother. [事实] She realized she needed to fully dedicate herself to the disease area if she wanted to discover something meaningful. [事实] She says the decision brought immediate joy despite uncertainty. [推测] Her grandmother’s death acted as the trigger that turned a long-held interest into action.

[18:56] The Fallopian Tube Insight

[事实] Sarna cites a Johns Hopkins Vogelstein lab paper arguing that many ovarian cancers begin in the fallopian tube. [事实] She studied how progress against other cancers often came from reaching the site of origin, such as Pap smears, colonoscopies, and mammograms. [事实] She began reading FDA filings and papers about prior attempts to access the fallopian tube or ovary without surgery. [推测] Her initial strategy was first-principles research: understand the disease origin, then study every prior access method.

[21:11] Talking to Physicians as Users

[事实] While still employed, Sarna began speaking with gynecologists and physicians to test the concept. [事实] After being dismissed by the front desk, she got an appointment with her own gynecologist and pitched the idea during the visit. [事实] That gynecologist later met her for coffee, liked the concept, and introduced her to physicians at Stanford and UC Davis. [推测] The episode presents user conversations as central to making a difficult medical-device idea credible.

[23:28] From Concept to Product Requirements

[事实] At first, the device was only a concept: a procedure during an annual exam that could collect cells without an incision, especially for high-risk women. [事实] Sarna says negative physician feedback was as valuable as positive feedback because it shaped design requirements. [事实] Simplicity and intuitive use were critical because physicians might be looking at a screen rather than their hands during the procedure. [事实] The handle was designed to support different hand sizes, including female physicians. [推测] The product design was influenced by both patient safety and overlooked ergonomics in medical tools.

[26:30] A Self-Navigating Catheter

[事实] Sarna says she also considered testing for uterine cancer and imagined a longer-term women’s health panel covering cervix, uterus, and fallopian tube. [事实] The final device was a self-navigating catheter using a linear everting balloon. [事实] The fallopian tube is only about one millimeter in inner diameter, has many twists, and lies flat unless pressurized. [事实] The textured balloon was designed to unfold into the fallopian tube, collect cells, and retract into a sheath to prevent contamination. [推测] The technical challenge was unusually high because the device had to be both delicate and effective in a poorly characterized anatomy.

[29:31] Clinical Questions and Missing Women’s Health Data

[事实] Sarna explains that the cancer often starts near the fimbria, finger-like extensions at the end of the fallopian tube. [事实] Getting as far into the fallopian tube as possible mattered for collecting relevant cells. [事实] She says basic literature on average fallopian tube length was missing. [推测] The lack of foundational data reflects the broader under-prioritization of women’s reproductive health.

[31:21] FDA Strategy and Early Team Building

[事实] Sarna worked with Cindy D’Amicus, who had strong FDA women’s health experience, to think through the regulatory process. [事实] Her first technical hire was her previous boss, a VP of R&D with multiple exits. [事实] She emphasizes that doing strong work in earlier jobs helped her attract experienced people later. [推测] The company’s early credibility depended heavily on the advisors and operators she could persuade to join.

[33:53] Being a Solo Founder in Women’s Health

[事实] Sarna says it took a year and a half to raise her first $250,000 in 2009-era market conditions. [事实] Investors did not yet treat women’s health as a major category, and one dismissed it as “bikini medicine.” [事实] She struggled to recruit cofounders, including because many early-career engineers she knew were men and women engineers often had hard-won stable roles. [事实] She says solo founding is tough because fundraising, customer work, and operations all fall on one person. [推测] Her story illustrates how category bias and founder identity can compound the normal difficulty of starting a company.

[39:06] Fundraising Rejection

[事实] Sarna faced many investor rejections and says she used to count 50, but later realized she had likely stopped counting after that. [事实] In one partner meeting, some investors talked to each other and showed things on their phones while she was pitching. [事实] She says experiences like this help explain why YC partners are protective of founders. [事实] She closed the next pitch after that bad meeting. [推测] The conversation frames rejection not as romantic hardship, but as emotionally costly work founders must recover from.

[43:25] Getting the First Capital Together

[事实] Investor Anula Jayasuria helped introduce Sarna to potential investors, including Darshana in Boston. [事实] After a promising partner meeting, Darshana initially said the partnership would not invest because Sarna was too risky. [事实] Sarna responded by offering to take no salary for two years and move back home with her parents. [事实] The firm agreed to invest $125,000 if she found a matching $125,000, which she did through Corinna Vini. [事实] Tim Draper later matched the $250,000, giving Sarna $500,000 to build a prototype. [推测] Sarna’s willingness to personally reduce burn helped convert a near-rejection into a financing path.

[48:23] Prototype, Clinical Studies, and FDA Clearance

[事实] With $500,000, Sarna completed enough bench testing and animal-tissue testing to show the prototype working. [事实] The first $250,000 closed in January 2012, the additional $250,000 came that summer, and by April 2013 she had a working prototype and raised $4.5 million. [事实] With the $4.5 million round, Envision completed two clinical studies and received FDA clearance. [事实] The first FDA clearance came in 2015, the second in 2016, and Sarna then raised $12 million. [推测] The company operated unusually leanly for a medical device startup.

[50:24] Clinical Data and Strategic Interest

[事实] The $12 million round supported early commercialization and another clinical study to strengthen claims to physicians. [事实] The FDA clearance covered collecting fallopian tube cell samples and examining them for malignant features. [事实] In a 50-patient study, the device found cancerous cells in all five cases where cancer was present in the fallopian tube. [事实] After this data, larger companies began reaching out, and Sarna says about seven showed initial interest. [推测] The five-positive-case result became a major credibility point, even though the company was still pre-revenue.

[53:33] The Emotional Decision to Sell

[事实] Before the later acquisition, another company had approached Sarna after FDA clearance and before the $12 million round. [事实] That earlier offer would have been personally life-changing, especially because she was supporting family and living very frugally. [事实] Sarna declined because she felt she needed to show the device could work in patients with cancer. [事实] Two years later, after more interest, she declined early offers around $100 million and $150 million before serious interest reached $275 million. [事实] She came to trust Boston Scientific’s team and culture and considered the difficulty of raising a large commercialization round. [推测] The sale decision balanced mission, investor outcomes, commercialization risk, and trust in the acquirer.

[57:14] Commercialization and COVID Disruption

[事实] Sarna stayed with the acquirer and led commercialization efforts even though she was fully accelerated at acquisition. [事实] She describes preselling to hospitals and being sent in to close large deals when contracts were close. [事实] The team was planning a major April 2020 launch after preparing in Boston in January 2020. [事实] COVID disrupted those launch plans. [推测] The product’s journey reached commercialization mode, but the pandemic changed the intended rollout.

[59:46] Without a Doubt and Mission

[事实] The hosts discuss the cover of Sarna’s book Without a Doubt, noting the visual emphasis on “out.” [事实] Sarna says the only thing she was truly without doubt about was that patients needed the product and that she wanted to work on it. [事实] She says everything else involved constant second-guessing. [推测] The title reflects persistence around the mission rather than total confidence in every decision.

[60:39] Helping Underrated Founders

[事实] Carolyn highlights Sarna’s statement that she wants to offer underrated people a path to pursuing their dreams. [事实] Sarna says this is what drew her to YC: helping people who may lack privilege or self-belief see the best version of themselves. [事实] The hosts close by emphasizing the need for more attention to women’s healthcare. [推测] Sarna’s current YC work appears connected to her own experience of being underestimated.

[61:57] Post-Interview Reflection

[事实] The hosts reflect that Sarna’s story contains heavy struggle, rejection, and persistence. [事实] They emphasize the difficulty of inventing a device for the fallopian tube, which is about a millimeter wide. [事实] They discuss how women’s health had long played second fiddle despite women being half the population. [事实] Both hosts mention family connections to ovarian or uterine cancer. [推测] The hosts see the episode as both a founder story and an argument for better diagnostic tools in women’s health.

播客点评/总结

This episode is strongest when it connects a deeply personal health scare to concrete startup decisions: how Sarna chose the problem, validated with physicians, recruited experienced people, navigated FDA clearance, and kept fundraising after repeated rejection.

The discussion is especially valuable for founders working in hard-tech, medical devices, healthcare, or overlooked categories. It shows that “talk to users” can mean speaking with physicians before a prototype exists, and that regulatory and clinical constraints can be part of the company-building strategy from the beginning.

[推测] The episode is less focused on detailed technical regulatory mechanics than on the founder journey, so listeners looking for a step-by-step FDA playbook may want supplemental material. Its main value is the combination of mission, resilience, product insight, and candid fundraising reality.

[推测] The episode is well suited for founders who feel underestimated, people interested in women’s health innovation, and listeners who want a realistic account of building in a category that was not yet fashionable.